The drug, made by Indivior, is used to treat pain as well as addiction to narcotic pain relievers.
In a lawsuit filed by the entities Thursday, they allege British company Indivior made efforts to get patients to switch to a dissolvable oral strip version of Suboxone.
The lawsuit alleged that when Indivior’s exclusive right to sell the drug was about to expire in 2009, it took steps to block generic versions from entering the market and that another company, MonoSol Rx, helped Indivior reach that goal, according to the report.
Indivior said in a statement cited by Reuters that it would continue to “vigorously defend” its position.
More articles on legal issues:
Troubled Calhoun Liberty signs contract with Alliant Management Services
UPMC sues law firm, actuary over hospital pension liability
House panel unanimously advances 6 public health bills: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.